- Home
- ANEB vs ACXP Comparison
ANEB vs ACXP Comparison
Compare ANEB & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANEB | ACXP |
|---|---|---|
| Founded | 2020 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.8M | 6.8M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ANEB | ACXP |
|---|---|---|
| Price | $2.17 | $3.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $143.67 |
| AVG Volume (30 Days) | 20.6K | ★ 77.3K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $3.17 |
| 52 Week High | $3.42 | $25.00 |
Technical Indicators
Market Signals| Indicator | ANEB | ACXP |
|---|---|---|
| Relative Strength Index (RSI) | 41.98 | 38.18 |
| Support Level | $1.91 | $3.98 |
| Resistance Level | $2.40 | $3.72 |
| Average True Range (ATR) | 0.14 | 0.35 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 51.77 | 13.20 |
Price Performance
Historical ComparisonAbout ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.